Company intelligence / Profile preview

Collateral Therapeutics

San Diego, California, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Collateral Therapeutics developed gene therapy products for cardiovascular diseases, targeting angiogenesis to treat angina and related conditions. Its primary candidate, Generx (Ad5FGF-4), showed improvement in myocardial perfusion in Phase II and moved to Phase IIb/III at the time of the company’s acquisition. A second candidate, Genvascor (Ad5.1FGF-4), was in Phase I/II. Post-acquisition compound development is unclear.

Therapeutic areas: Cardiovascular
Modalities: Gene therapy
Industry: Biotech

Partnerships

Schering AG (exclusive worldwide licensee, and then acquirer)

Beyond the preview

Go deeper on Collateral Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Collateral Therapeutics.

Explore the full profile